Drug Profile
PBI 4419
Alternative Names: PBI-4419Latest Information Update: 14 Oct 2019
Price :
$50
*
At a glance
- Originator ProMetic Life Sciences
- Developer Allist Pharmaceuticals; Liminal BioSciences
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute kidney injury; Fibrosis; Inflammation
Most Recent Events
- 03 Oct 2019 Prometic Life Sciences is now called Liminal BioSciences
- 28 Jun 2018 No recent reports of development identified for preclinical development in Acute kidney injury in Canada (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Fibrosis in Canada (PO)